An Effective Virtual Screening Protocol To Identify Promising p53-MDM2 Inhibitors

The p53-MDM2 interaction is a well-known protein-protein contact, and its disruption is a key event for p53 activation and induction of its oncosuppressor response. The design of small molecules that can block the p53-MDM2 interaction and reactivate the p53 function is a promising strategy for cancer therapy. To date, several compounds have been identified as p53-MDM2 inhibitors, and X-ray structures of MDM2 complexed with several ligands are available in the Brookhaven Protein Data Bank. These data have been exploited to compile a hierarchical virtual screening protocol. The first steps were aimed at selecting a focused library, which was submitted in parallel to docking and pharmacophore model alignment. Selected compounds were subjected to inhibition assays of both cellular vitality (MTT) and p53-MDM2 interaction (ELISA and co-immunoprecipitation), disclosing four nanomolar inhibitors.

[1]  A. Levine,et al.  Functions of the MDM2 oncoprotein , 1999, Cellular and Molecular Life Sciences CMLS.

[2]  T. Clackson,et al.  A hot spot of binding energy in a hormone-receptor interface , 1995, Science.

[3]  Volkhard Helms,et al.  Druggability of dynamic protein-protein interfaces. , 2012, Current pharmaceutical design.

[4]  M. Noble,et al.  Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency. , 2011, Journal of medicinal chemistry.

[5]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[6]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[7]  Maria M. M. Santos,et al.  Synthesis and evaluation of spiroisoxazoline oxindoles as anticancer agents. , 2014, Bioorganic & medicinal chemistry.

[8]  Olivier Sperandio,et al.  Rationalizing the chemical space of protein-protein interaction inhibitors. , 2010, Drug discovery today.

[9]  S. Agarwal,et al.  The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma , 2015, Cell Death Discovery.

[10]  Jonathan C. Fuller,et al.  Predicting druggable binding sites at the protein-protein interface. , 2009, Drug discovery today.

[11]  P. Furet,et al.  The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction. , 2012, Bioorganic & Medicinal Chemistry Letters.

[12]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[13]  Dennis M. Krüger,et al.  Comparison of Structure‐ and Ligand‐Based Virtual Screening Protocols Considering Hit List Complementarity and Enrichment Factors , 2010, ChemMedChem.

[14]  Olivier Sperandio,et al.  Designing Focused Chemical Libraries Enriched in Protein-Protein Interaction Inhibitors using Machine-Learning Methods , 2010, PLoS Comput. Biol..

[15]  Wei Wang,et al.  Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery , 2010, Cell cycle.

[16]  J. Matthews,et al.  Protein-protein interactions in human disease. , 2005, Current opinion in structural biology.

[17]  Xin Huang,et al.  Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction. , 2009, Journal of medicinal chemistry.

[18]  Maxwell D Cummings,et al.  Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. , 2005, Journal of medicinal chemistry.

[19]  Xueliang Fang,et al.  Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy. , 2006, Journal of medicinal chemistry.

[20]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[21]  T. Holak,et al.  Exhaustive Fluorine Scanning toward Potent p53–Mdm2 Antagonists , 2012, ChemMedChem.

[22]  Jonathan Y. Mane,et al.  Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions. , 2010, Journal of molecular graphics & modelling.

[23]  Hyeong Jun An,et al.  Estimating the size of the human interactome , 2008, Proceedings of the National Academy of Sciences.

[24]  Su Qiu,et al.  Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. , 2006, Journal of medicinal chemistry.

[25]  D. Bernard,et al.  Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment , 2014, Journal of medicinal chemistry.

[26]  Nathan Brown,et al.  Knowledge-based virtual screening: application to the MDM4/p53 protein-protein interaction. , 2009, Methods in molecular biology.

[27]  Pedro J. Ballester,et al.  Prospective virtual screening for novel p53–MDM2 inhibitors using ultrafast shape recognition , 2014, Journal of Computer-Aided Molecular Design.

[28]  Barbara Costa,et al.  Human Glioblastoma Multiforme: p53 Reactivation by a Novel MDM2 Inhibitor , 2013, PloS one.

[29]  Alexander Dömling,et al.  The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious. , 2011, Angewandte Chemie.

[30]  Fang Liu,et al.  Effective Screening Strategy Using Ensembled Pharmacophore Models Combined with Cascade Docking: Application to p53-MDM2 Interaction Inhibitors , 2013, J. Chem. Inf. Model..

[31]  Shaomeng Wang,et al.  Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics , 2012 .

[32]  J. Canon,et al.  Structure-based design of novel inhibitors of the MDM2-p53 interaction. , 2012, Journal of medicinal chemistry.

[33]  Guoqiang Dong,et al.  Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction. , 2012, Journal of medicinal chemistry.

[34]  X. Zhao,et al.  HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function , 2008, Oncogene.

[35]  M. Hollstein,et al.  p53 and human cancer: the first ten thousand mutations. , 2000, Advances in cancer research.

[36]  Jared K Burks,et al.  The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias , 2010, Molecular Cancer Therapeutics.

[37]  L. Vassilev.  p53 Activation by small molecules: application in oncology. , 2005, Journal of medicinal chemistry.

[38]  M. Trincavelli,et al.  A Rapid and Efficient Immunoenzymatic Assay to Detect Receptor Protein Interactions: G Protein-Coupled Receptors , 2014, International journal of molecular sciences.

[39]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[40]  Weisi Wang,et al.  Identification of novel inhibitors of p53–MDM2 interaction facilitated by pharmacophore-based virtual screening combining molecular docking strategy , 2013 .

[41]  Shaomeng Wang,et al.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. , 2009, Annual review of pharmacology and toxicology.

[42]  M. Noble,et al.  Analysis of chemical shift changes reveals the binding modes of isoindolinone inhibitors of the MDM2-p53 interaction. , 2008, Journal of the American Chemical Society.

[43]  E. Novellino,et al.  Apoptosis Therapy in Cancer: The First Single-molecule Co-activating p53 and the Translocator Protein in Glioblastoma , 2014, Scientific Reports.

[44]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[45]  J. Deschamps,et al.  Structure-based design of potent non-peptide MDM2 inhibitors. , 2005, Journal of the American Chemical Society.